Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation

被引:15
作者
Mardigyan, V
Tchervenkov, J
Metrakos, P
Barkun, J
Deschenes, M
Cantarovich, M
机构
[1] McGill Univ, Dept Med, Multi Organ Transplant Program, Royal Victoria Hosp,Hlth Ctr, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Dept Surg, Multi Organ Transplant Program, Royal Victoria Hosp,Hlth Ctr, Montreal, PQ H3A 1A1, Canada
关键词
tacrolimus; mycophenolate mofetil; mycophenolic acid; AUC; liver transplantation;
D O I
10.1016/j.clinthera.2005.04.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Tacrolimus and mycophenolate mofetil (MMF) are immunosuppressive agents used for the prevention of allograft rejection in liver transplant recipients. Therapeutic drug monitoring (TDM) of tacrolimus is routinely performed using the trough (predose; time 0) plasma drug concentration (C-0). In kidney and heart transplant recipients, TDM of MMF has proved to be effective in preventing acute rejection. Some studies a poor predictor of drug have shown that C-0 exposure (represented by AUC), and that concentrations measured after dosing may have a stronger correlation with AUC. However, routine TDM of MMF has not been widely accepted and dose adjustments are usually performed based on adverse effects. Objective: The aim of the present study was to determine whether plasma drug concentrations measured after dosing would be better correlated with the tacrolimus and mycoplasmic acid (MPA) (the active metabolite of MMF) AUC(0-12) values compared with C-0 in liver transplant recipients >= 12 months after transplantation. Methods: This study was conducted at the Multi-Organ Transplant Program research suite, Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada. Liver transplant recipients aged >= 18 years receiving tacrolimus and MMF >= 12 months after transplantation were enrolled. The plasma tacrolimus and MPA concentrations were measured before the first morning dose (CO) and at 30 minutes (MPA only) and 1, 2, 3, 4, 6, 8, and 12 hours after the first morning dose (C-30 (min), C-1, C-2 C-3, C-4, C-6, C-8, and C-12, respectively). Results: The study population consisted of 14 patients (7 women, 7 men; mean [SD] age, 57 [16] years; mean [SD] body weight, 75.4 [20.7] kg [range, 44107 kg]; mean time posttransplant, 42 [30] months). All postdose concentrations (except C-30 (minw) [MPA]) were better correlated with AUC(0-12) values for tacrolimus and MPA compared with C-0. For tacrolimus, the correlations of C-0, C-2, C-3, and C-4 with AUC(0-12) were 0.67, 0.83, 0.84, and 0.88, respectively, and for MPA, they were 0.46, 0.73, 0.69, and 0.68, respectively. For tacrolimus, the concentration best correlated with AUC(0-12) was C4. For MPA, the concentration best correlated with AUC(0-12) was C-8. Conclusion: This study in adult liver transplant recipients suggests that for both tacrolimus and MPA, C-2, C-3, and C-4 are better surrogates of AUC(0-12) compared with C-0. Copyright (c) 2005 Excerpta Medica, Inc.
引用
收藏
页码:463 / 469
页数:7
相关论文
共 22 条
[1]   TIMING, SIGNIFICANCE, AND PROGNOSIS OF LATE ACUTE LIVER ALLOGRAFT-REJECTION [J].
ANAND, AC ;
HUBSCHER, SG ;
GUNSON, BK ;
MCMASTER, P ;
NEUBERGER, JM .
TRANSPLANTATION, 1995, 60 (10) :1098-1103
[2]  
[Anonymous], CLIN PHARMACOKINETIC
[3]   Therapeutic drug monitoring of tacrolimus early after liver transplantation [J].
Braun, F ;
Peters, B ;
Schütz, E ;
Lorf, T ;
Undre, N ;
Oellerich, M ;
Ringe, B .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1538-1539
[4]  
Bullingham RES, 1996, TRANSPLANT P, V28, P925
[5]  
Cantarovich M, 1998, CLIN TRANSPLANT, V12, P243
[6]   Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus [J].
Cantarovich, M ;
Fridell, J ;
Barkun, J ;
Metrakos, P ;
Besner, JG ;
Deschênes, M ;
Alpert, E ;
Aalamian, Z ;
Tchervenkov, JI .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1460-1461
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? [J].
Cox, VC ;
Ensom, MHH .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :137-157
[9]   Limited sampling strategy for mycophenolic acid area under the curve [J].
Filler, G ;
Mai, I .
THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :169-173
[10]   Mycophenolate mofetil in renal allograft recipients - A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection [J].
Halloran, P ;
Mathew, T ;
Tomlanovich, S ;
Groth, C ;
Hooftman, L ;
Barker, C .
TRANSPLANTATION, 1997, 63 (01) :39-47